Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $500
10/19/2026
Impact: 80
Healthcare
Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on Natera (NASDAQ: NTRA) and increased the price target from $375 to $500. This adjustment reflects a positive outlook for the company's performance.
AI summary, not financial advice
Share: